DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
Authors:
- 7 September 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 548, 215899
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (/ NCI R50CA243878)
- National Cancer Institute (P30 CA014089)
- National Cancer Institute (R35 CA209859)
This publication has 71 references indexed in Scilit:
- Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotypeInternational Journal of Cancer, 2020
- NANOG-Dependent Metabolic Reprogramming and Symmetric Division in Tumor-Initiating Stem-like Cells2018
- A Three‐Pronged Epigenetic Approach to the Treatment of Hepatocellular CarcinomaHepatology, 2018
- Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI‐110) in Hepatocellular CarcinomaHepatology, 2018
- Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerMolecular Oncology, 2017
- MethyLight and Digital MethyLight2017
- Existence of cancer stem cells in hepatocellular carcinoma: myth or reality?Hepatology International, 2016
- Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation2016
- DNA methylation‐based prognosis and epidrivers in hepatocellular carcinomaHepatology, 2015
- Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinomaHepatology, 2012